Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis

Cancer Letters

Volumn 385, Issue , 2017, Pages 215-224

  Tanaka, Kosuke ^a,b   Osada, Hirotaka ^a,b   Murakami Tonami, Yuko ^a   Horio, Yoshitsugu ^a   Hida, Toyoaki ^a   Sekido, Yoshitaka ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer stem cell; CD44; Hippo pathway; Malignant mesothelioma; Statin; YAP

Indexed keywords

CD44V6 ANTIGEN; FLUINDOSTATIN; HERMES ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MERLIN; MESSENGER RNA; MEVALONIC ACID; ONCOPROTEIN; SIMVASTATIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BAP1 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; HIPPO PROTEIN, HUMAN; INDOLE DERIVATIVE; LATS2 PROTEIN, HUMAN; MONOUNSATURATED FATTY ACID; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BAP1 GENE; BINDING SITE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CELL DENSITY; CONTROLLED STUDY; GENE; GENE MUTATION; HIPPO SIGNALING PATHWAY; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE TUMOR SUPPRESSOR 2 GENE; MAJOR CLINICAL STUDY; MESOTHELIOMA CELL LINE; MIGRATION INHIBITION; NEUROFIBROMATOSIS TYPE 2 GENE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; CELL MOTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LUNG NEOPLASMS; MESOTHELIOMA; MEVALONIC ACID; MUTATION; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NEUROFIBROMIN 2; PHOSPHOPROTEINS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIMVASTATIN; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 85002406528     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.10.020     Document Type: Article

References (50)

1. [1] Carbone, M., Ly, B.H., Dodson, R.F., Pagano, I., Morris, P.T., Dogan, U.A., et al. Malignant mesothelioma: facts, myths, and hypotheses. J. Cell Physiol. 227 (2012), 44–58.
2. [2] Yang, H., Testa, J.R., Carbone, M., Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr. Treat. Options Oncol. 9 (2008), 147–157.
3. [3] Robinson, B.W., Lake, R.A., Advances in malignant mesothelioma. N. Engl. J. Med. 353 (2005), 1591–1603.
4. [4] Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21 (2003), 2636–2644.
5. [5] Reid, A., de Klerk, N.H., Magnani, C., Ferrante, D., Berry, G., Musk, A.W., et al. Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis. Thorax 69 (2014), 843–850.
6. [6] Sekido, Y., Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 101 (2010), 1–6.
7. [7] Bianchi, A.B., Mitsunaga, S.I., Cheng, J.Q., Klein, W.M., Jhanwar, S.C., Seizinger, B., et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 10854–10858.
8. [8] Sekido, Y., Pass, H.I., Bader, S., Mew, D.J., Christman, M.F., Gazdar, A.F., et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 55 (1995), 1227–1231.
9. [9] Huang, J., Wu, S., Barrera, J., Matthews, K., Pan, D., The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122 (2005), 421–434.
10. [10] Tapon, N., Harvey, K.F., Bell, D.W., Wahrer, D.C., Schiripo, T.A., Haber, D., et al. Salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 110 (2002), 467–478.
11. [11] Zhao, B., Tumaneng, K., Guan, K.L., The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 13 (2011), 877–883.
12. [12] Pan, D., Hippo signaling in organ size control. Genes Dev. 21 (2007), 886–897.
13. [13] Pan, D., The hippo signaling pathway in development and cancer. Dev. Cell 19 (2010), 491–505.
14. [14] Harvey, K., Tapon, N., The Salvador-Warts-Hippo pathway – an emerging tumour-suppressor network. Nat. Rev. Cancer 7 (2007), 182–191.
15. [15] Overholtzer, M., Zhang, J., Smolen, G.A., Muir, B., Li, W., Sgroi, D.C., et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 12405–12410.
16. [16] Zender, L., Spector, M.S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006), 1253–1267.
17. [17] Badouel, C., Garg, A., McNeill, H., Herding Hippos: regulating growth in flies and man. Curr. Opin. Cell Biol. 21 (2009), 837–843.
18. [18] Murakami, H., Mizuno, T., Taniguchi, T., Fujii, M., Ishiguro, F., Fukui, T., et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71 (2011), 873–883.
19. [19] Yokoyama, T., Osada, H., Murakami, H., Tatematsu, Y., Taniguchi, T., Kondo, Y., et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 29 (2008), 2139–2146.
20. [20] Demierre, M.F., Higgins, P.D., Gruber, S.B., Hawk, E., Lippman, S.M., Statins and cancer prevention. Nat. Rev. Cancer 5 (2005), 930–942.
21. [21] Rubins, J.B., Greatens, T., Kratzke, R.A., Tan, A.T., Polunovsky, V.A., Bitterman, P., Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med. 157 (1998), 1616–1622.
22. [22] Wang, Z., Wu, Y., Wang, H., Zhang, Y., Mei, L., Fang, X., et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E89–E98.
23. [23] Mandal, C.C., Ghosh-Choudhury, N., Yoneda, T., Choudhury, G.G., Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J. Biol. Chem. 286 (2011), 11314–11327.
24. [24] Ponta, H., Sherman, L., Herrlich, P.A., CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 4 (2003), 33–45.
25. [25] Zoller, M., CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 11 (2011), 254–267.
26. [26] Stamenkovic, I., Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol. 200 (2003), 448–464.
27. [27] Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F., Dick, J.E., Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12 (2006), 1167–1174.
28. [28] Collins, A.T., Berry, P.A., Hyde, C., Stower, M.J., Maitland, N.J., Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65 (2005), 10946–10951.
29. [29] Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., et al. Identification of pancreatic cancer stem cells. Cancer Res. 67 (2007), 1030–1037.
30. [30] Taube, J.H., Herschkowitz, J.I., Komurov, K., Zhou, A.Y., Gupta, S., Yang, J., et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 15449–15454.
31. [31] Morrison, H., Sherman, L.S., Legg, J., Banine, F., Isacke, C., Haipek, C.A., Gutmann, D.H., et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15 (2001), 968–980.
32. [32] Yu, S., Cai, X., Wu, C., Wu, L., Wang, Y., Liu, Y., et al. Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. Oncotarget 6 (2015), 2951–2965.
33. [33] Ponta, H., Sleeman, J., Dall, P., Moll, J., Sherman, L., Herrlich, P., CD44 isoforms in metastatic cancer. Invasion Metastasis 14 (1994), 82–86.
34. [34] Dall, P., Heider, K.H., Hekele, A., von Minckwitz, G., Kaufmann, M., Ponta, H., et al. Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res. 54 (1994), 3337–3341.
35. [35] Sanchez Lockhart, M., Hajos, S.E., Basilio, F.M., Mongini, C., Alvarez, E., Splice variant expression of CD44 in patients with breast and ovarian cancer. Oncol. Rep. 8 (2001), 145–151.
36. [36] Porcel, J.M., Esquerda, A., Rodriguez-Panadero, F., Martinez-Iribarren, A., Bielsa, S., The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies. J. Thorac. Oncol. 6 (2011), 190–194.
37. [37] Lu, L., Li, Y., Kim, S.M., Bossuyt, W., Liu, P., Qiu, Q., et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 1437–1442.
38. [38] St John, M.A., Tao, W., Fei, X., Fukumoto, R., Carcangiu, M.L., Brownstein, D.G., et al. Mice deficient of LATS1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat. Genet. 21 (1999), 182–186.
39. [39] Muramatsu, T., Imoto, I., Matsui, T., Kozaki, K., Haruki, S., Sudol, M., et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 32 (2011), 389–398.
40. [40] Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147 (2011), 759–772.
41. [41] Song, S., Ajani, J.A., Honjo, S., Maru, D.M., Chen, Q., Scott, A.W., et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 74 (2014), 4170–4182.
42. [42] Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 16 (2014), 357–366.
43. [43] Clendening, J.W., Pandyra, A., Boutros, P.C., El Ghamrasni, S., Khosravi, F., Trentin, G.A., et al. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 15051–15056.
44. [44] Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360 (2009), 679–691.
45. [45] Aviles, A., Nambo, M.J., Neri, N., Castaneda, C., Cleto, S., Huerta-Guzman, J., Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med. Oncol. 24 (2007), 227–230.
46. [46] Santini, D., Vincenzi, B., Galluzzo, S., Battistoni, F., Rocci, L., Venditti, O., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 13 (2007), 4482–4486.
47. [47] Bott, M., Brevet, M., Taylor, B.S., Shimizu, S., Ito, T., Wang, L., et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43 (2011), 668–672.
48. [48] Testa, J.R., Cheung, M., Pei, J., Below, J.E., Tan, Y., Sementino, E., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43 (2011), 1022–1025.
49. [49] Yu, H., Pak, H., Hammond-Martel, I., Ghram, M., Rodrigue, A., Daou, S., et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 285–290.
50. [50] Scheuermann, J.C., de Ayala Alonso, A.G., Oktaba, K., Ly-Hartig, N., McGinty, R.K., Fraterman, S., et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465 (2010), 243–247.